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SUMMARY 
 
This document has been prepared by the IUPAC Medicinal Chemistry section 
and is backed by a large number of scientists, many of whom have had direct involve-
ment and whose names appear at the end of the article. 
 This work discusses the role that the discovery of new medicinal agents has in 
the development of societies as well as in the conservation of biodiversity in terms of the 
work carried out on natural products. 
 Also included are several recommendations for countries which are presently in 
search of their own scientific and technological development in medicinal agents. 
 The IUPAC Medicinal Chemistry section would appreciate the collaboration of 
the scientific societies in every country to aid in the diffusion of this document. 
Keywords: Medicinal Chemistry.- Biodiversity.- Development of Societies. 
 
RESUMEN 
 
La Química médica en el desarrollo de las Sociedades. Biodiversidad y Pro-
ductos naturales 
Se presenta un documento de opinión elaborado por la sección de Medicinal 
Chemistry de IUPAC, que cuenta además con el acuerdo de un buen número de científi-
cos, algunos de los cuales figuran al final del trabajo. 
Se plantea el papel que puede tener el descubrimiento de medicamentos en el 
desarrollo de las sociedades y mantenimiento de la biodiversidad en base a los trabajos 
en productos naturales. 
Se plantean recomendaciones de aplicación en los países que están en la bús-
queda de su desarrollo científico y tecnológico en el medicamento. 
Es intención de la sección de Medicinal Chemistry de IUPAC su difusión inter-
nacional, por lo que agradecen la colaboración de las sociedades científicas de los dife-
rentes países. 
Palabras Clave: Medicinal Chemistry.- Biodiversidad.- Desarrollo de los pueblos. 
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 Modern times have seen globalization of all human endeavors 
accompanied by a seamless, sans frontiers, diffusion of culture, ideas and 
science across traditional boundaries of territories, cultures and societies.  
However, all societies are not at the same level of development and a sig-
nificant challenge still lies in respecting and harnessing our differences to 
insure peace, justice and liberty for all. 
 For example, within the context of the life sciences a man-made 
medicinal agent should receive special, international attention.  Any com-
pound that can help restore lost health or prevent a disease should be 
made available to all countries, regardless of the continental location or 
the degree of societal development.  The only limits that should exist are 
those which are organizational, linked to preparation, distribution, etc. 
 Presently there are countries which are the discoverers of medici-
nal agents and there are countries which are simply consumers.  Likewise, 
there are countries whose legislation pertaining to intellectual property 
rights are quite sophisticated while there are others who do not have this 
type of legislation at all.  Some countries are in search of development 
with an overabundance of natural resources and biodiversity while others 
have the potential for scientific and technological exploitation but lack 
such resources.  In this wide panorama, the field of chemistry can play an 
important role since medicinal agents are chemical products which, in 
many cases, are often modified if not entirely prepared by chemical reac-
tions.  Likewise, biodiversity is attributable to chemical constituents of 
plants with an array of complex structures, many of which have not yet 
succumbed to total, practical syntheses by man.  To lose biodiversity is to 
lose information of great potential value. 
 This article intends to refine and further promote ideas proposed 
during earlier projects of the IUPAC Medicinal Chemistry section (1-3).  
Specifically, the authors seek to enhance the transfer of science and tech-
nology associated with drug discovery and development between devel-
oped and developing societies in the most mutually beneficial scenarios 
possible. 
 
Inverting The Model 
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 Irrespective of administrative or political considerations, compa-
nies and centers having high levels of development need to be brought 
together with those which lack it by means of joint projects within the 
broad field of chemistry and, especially, within the distinct area of bio-
logically active compounds. Various modes of interaction can be pro-
posed:  the most often used is one wherein samples of materials from de-
veloping countries with biodiversity are extracted and transported for 
study in developed societies.  We make a case for an inversion of this 
traditional model, namely that of offering technology to the countries 
with biodiversity so that they themselves may carry out the necessary 
developmental work.  Chemical research conducted in the country where 
samples originate would enhance the country’s scientific development.  
Competitive capacity, research methodology and the infrastructure could 
be the focus of negotiation and agreement.  The contributions to chemical 
research on bioactive molecules that biodiversity-rich, developing coun-
tries may be able to then return can be ascertained on the basis of: 
 
¾ Strengths: 
− Biological material, both of animal and vegetable origin, with 
demonstrated or potential activity. 
− Traditional knowledge concerning biological activities, linked 
to plants or animals. 
 
¾ Weaknesses: 
− Infrastructure deficiencies which cause difficulties for con-
ducting scientific research. 
 
 Importantly, the salient features of such programs should provide 
for:  conservation of biodiversity; equitable intellectual property 
rights/duties; and, development of scientific re-
sources/facilities/infrastructure. 
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Medicinal Chemistry and Biodiversity 
 
 Realizing that biodiversity can be lost by man-made cataclysms 
such as the construction of large public works or by natural catastrophes 
such as fires, volcanoes etc., Medicinal Chemistry can function as a great 
ally by emphasizing the eco-balance between life and its surroundings, 
plants and micro-fauna and other relationships.  Medicinal Chemistry also 
recognizes the symbiotic interaction between native communities and cul-
tures as a foundation and wellspring for potential discoveries.  These 
interrelationships must be nurtured and their key elements preserved.  
Researchers studying natural medicinal agents subscribe to this rationale.  
Their analysis, evaluation and effective utilization of available resources 
can greatly assist toward maintaining the elements of biodiversity while 
promoting scientific advances.  Alternatively, in developing countries 
whose economies are based on the exploitation of agricultural and live-
stock resources principally geared to the production of cash crops and 
immediate products, there is great pressure on their natural space.  Conse-
quently, there is also great pressure toward the potential elimination of 
their natural flora.  Thus, the relationships between biodiversity, opportu-
nity and the structuring of various alliances become especially important 
relative to the immediate financial needs of a developing country.  In this 
light, however, biodiversity and Medicinal Chemistry must find a way to 
collaborate and optimize opportunities based on new alliances and tech-
nology transfer that is not based-upon pure economics.  Enormous bene-
fits can accrue in the fields of education, scientific research, and innova-
tion when an approach, other than immediate financial gain is taken. 
 Some examples can be illustrative.  The “uña de gato,” Uncaria 
tomentosa, DC, is a liana which has long been used by native communi-
ties of South America.  However, the people from the countries where the 
plant grows became wary of exporting extracts for Medicinal Chemistry 
research because they thought they might not receive commensurate 
benefits.  Ultimately the plant became offered on the net, in any quantity 
anywhere in the world by a few financially opportunistic companies.  The 
result is that the opportunity toward incorporating technology and techno-
logical development for the countries that originally possessed the plant 
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has been lost.  Alternatively, the domestication of plants, such as the Ca-
tharanthus roseus G. Don of great interest in the production of anti-
cancer alkaloids like vincristine, represents a form of conservation of bio-
diversity, of training in agricultural techniques of economic interest, and 
of the creation of a local chemical industry. 
 
Medicinal Chemistry and Ownership of Natural Resources 
 
 Recognizing the sovereign rights that each country has over its 
resources (4), the aim of this report is to prompt compromises between 
developed countries and developing countries in the area of ownership.  
New circumstances (5) have emerged that suggest reform of the tradi-
tional system of patents essential for commercialization and diffusion of 
science.  Presently, when a native community produces a unique cloth, it 
can be copied by the whole world because it is not legally protected.  Al-
ternatively, when an entity in a developed country copies and registers 
modifications based on the designs of a native community, absolutely no 
one, not even the original artists, can legally copy them (6).  It could be 
argued that the native community has the sole responsibility to register its 
work in order to obtain legal protection.  However, such countries are 
typically unable to do this because of a lack of knowledge regarding these 
types of procedures or due to a scarcity of the means to achieve such 
ends.  The same situation can happen with a galenic preparation of a plant 
that has biological activity when initially used by a traditional culture. 
 Establishing ownership may not be simple.  It is imperative to 
begin by defining the discoverer (7).  In the discovery of medicinal 
agents, by traditional ways of Medicinal Chemistry, this can correspond 
to an individual researcher or to an entire research team.  In plants with 
therapeutic applications originating from native communities, the ques-
tion is much more complicated.  Here we are speaking more of a “chain” 
of inventors.  This can result in problems when it comes to the selection 
of the beneficiaries and the distribution of the benefits obtained.  A matter 
of equal importance is the fact that certain cultures hold nature to be sa-
cred and look askance at any attempts at its legal protection as a prelude 
to commercialization. 
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 Whether the traditional use of a plant for a given pathology consti-
tutes public property and prior art is a vexing question.  The protection of 
knowledge, within the context of plants with biological activity, cannot be 
easily accomplished via patents and it becomes necessary to search for 
further avenues.  From the standpoint of equity, answers may be able to 
be found during the transfer of knowledge.  Consider that the number of 
plants which are presently used in their original form in therapeutics is 
quite limited.  In practice it is the process of bio-directed fractionation of 
plant extracts that eventually permits us to find compounds which then 
typically also undergo further structural modification to ultimately pro-
vide preferred molecules that are more active and less toxic.  Conse-
quently, in this type of scenario a patent covering the initial plant material 
may not be adequate. The solution to this scenario of “plant-
development” can lead to an impasse precisely for the countries in search 
of development, thereby possibly losing by default the possibilities for the 
use of their biodiversity. 
 Economic compensation for historical knowledge should not be 
lost during the overall development process because the living materials 
may have needed protection and conservation, sometimes throughout cen-
turies, in order to ultimately afford the current validation of their use.  
This effort might be compensated for through a contract, establishing roy-
alties that could be obtained when commercialization takes place.  In line 
with our previous discussion, the contract might also specify in advance 
of commercialization and as part of a collaborative development venture, 
the training of persons and the acquisition of equipment and technologies 
as well as the more typical payment for samples.  For example, compen-
sation could be provided to the persons that provide the plant, make the 
extracts, and carry out biological assays, in such a way that each one can 
maintain his or her own interest and ultimate stake in commercialization.  
The country obtains benefits directly through taxation corresponding to 
the activities, and more importantly, through the scientific and techno-
logical upgrading of its society.  The possibility of regional subsidiary or 
local companies playing a more important role in the transference of re-
search and technology in such collaborative scenarios should also be seri-
ously considered.   
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 In countries with emerging economies, biodiversity and related 
activities constitute “green gold.”  For this reason, at times, the govern-
ments assume quick, financially-driven policies that can sometimes be 
contrary to eco-relationships.  Thus, both parties must be prepared to 
adopt longer-range planning considerations into their decision-making 
processes.  Equity and equal opportunity must be given to protect the dis-
coveries made by any society.  This principle of equity can ameliorate any 
misunderstanding arising out of the actions of medicinal chemists in de-
veloped countries in their relationship with their counterparts in develop-
ing countries. 
 
Summarial Points 
 
¾ Medicinal Chemistry research on extracts from plants and other living 
organisms that leads to the discovery of therapeutic agents, can also 
be an important factor toward maintaining biodiversity. 
¾ Relationships between societies which possess important biodiversity 
and developed societies which possess advanced technological proc-
esses should be based on the principles of equity.  They should oper-
ate by means of collaborative contracts which acknowledge progres-
sion of scientific research in such a way that the immediate financial 
aspects are not considered to be of primary interest but rather only a 
legitimate, longer-term consequence of such partnering (8,9). 
¾ Since all of humanity benefits from the discovery of new drugs, all 
societies should collaborate in the preservation and evaluation of the 
areas of great diversity from which such structures might emerge.  
This could be carried out through investments made by pharmaceuti-
cal companies to help preserve this type of land (e.g. of great biodi-
versity, of fragile environment, or where promising species prosper) 
and through the promotion of localized searches done in collaborative 
settings that can allow for both immediate development of identified 
actives and sustained cultivation of undefined biodiversity.  
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Additional Recommendations 
 
¾ Strengthen international relationships on these types of research pro-
jects, particularly  including countries at different levels of develop-
ment. 
¾ Utilize university-company relationships within less-developed coun-
tries. 
¾ Strengthen international relationships between scientists and the au-
thorities responsible for research in various countries. 
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